One paper contained several experiments
Trammell and colleagues investigated NR effects on NAD metabolism in humans and mice. The human work found dose-dependent changes in blood NAD-related compounds after single oral NR exposures. An often-cited increase of up to 2.7-fold came from a pilot in one individual. The paper also compared precursor pharmacokinetics in mouse liver. [1]
The animal comparison and the human observations are different evidence. A finding about superior mouse-liver pharmacokinetics should not be presented as a human head-to-head trial showing that a retail NR product is better than other NAD precursors. [1]
Why mixed-species papers need careful summaries
A research article can legitimately combine mechanistic animal work with early human testing. The reader’s job is to keep the species attached to each result. A title mentioning humans does not mean every comparison in the paper was performed in people.
Before accepting a superiority claim, find the experiment that directly compared the alternatives. Identify the subjects, administered compounds, sample type and endpoint. If those details change between the supporting experiment and the advertised product, the conclusion needs to narrow accordingly.
The same discipline applies to the one-person pilot. It can demonstrate that a measurable response occurred in that individual under those conditions. It cannot establish a typical response or the range of responses consumers should expect. A maximum value is not a population average.
Bioavailability is a step in the evidence chain
Demonstrating an oral biological response is useful. It helps justify subsequent studies and can guide sampling schedules. It is still different from showing an improvement in symptoms, function or long-term health.
When a product emphasizes absorption, ask what was actually measured: the administered molecule in circulation, a downstream metabolite, a tissue concentration or a functional outcome. These are related questions, but they are not synonyms. A percentage or fold change needs its original measurement label.
The eight-volunteer pharmacokinetic study adds another early human design. Read it as a separate experiment rather than combining selected numbers into a universal conversion rate.
For an offer involving NMN or NAD+ infusions, this NR paper is not direct evidence for that formulation and route. The ingredient guide makes that distinction explicit. The early oral NR work is scientifically important because it established a basis for further human research. It does not establish that every oral formulation reaches every target tissue equally or that a larger blood response produces a better clinical outcome. A fair evidence table should mark every animal result explicitly and keep one-person observations separate from group-level estimates of a response.